AllSight
Companies · TENX · Pharmaceutical Preparations

TENAX THERAPEUTICS, INC. (TENX)

TENAX THERAPEUTICS, INC. (TENX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

TENAX THERAPEUTICS, INC. (TENX) stock — financials & valuation

Key numbers for TENAX THERAPEUTICS, INC. (TENX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 35/100 — a percentile rank of TENAX THERAPEUTICS, INC.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Market cap$503.0M
EV / EBITDA-5.6×
Return on equity-57.1%
Debt / equity0.0×
Dividend yield0.0%

Is TENAX THERAPEUTICS, INC. overvalued? P/B looks fair vs its 5-year range.

Independent of the events above — derived from TENAX THERAPEUTICS, INC.’s own financial statements and shown as context, never as advice.

Aug 10, 2026
Phase 3 misses both main endpoints; subgroup signals keep a regulatory path alive
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact